NKTT120: Interim Phase I data

Interim data from 11 patients with stable sickle cell disease in an open-label, dose-escalation, U.S. Phase I trial showed that single doses of 0.001, 0.003, 0.01 and 0.03 mg/kg NKTT120 were well tole...